Skip to content

Implementing “Community-based approach for lowering stress through mindfulness in Chicago” (CALM-Chicago) for depression and hypertension: Study protocol of a proof-of-concept trial

Allison J. Carroll, Paris Davis, Larissa R. Reed, Asia Ellis, Namratha R. Kandula, Abel Kho, Quentin R. Youmans, Carly Maletich, Mark D. Huffman, Justin Dean Smith, Inger Burnett-Zeigler

Contemporary Clinical Trials Communications October 28, 2026 DOI: 10.1016/j.conctc.2026.101702 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Single-arm type 1 hybrid effectiveness-implementation study Qualitative Peer reviewed
Population Black/African American adults aged 18 or older with elevated depressive symptoms (PHQ-9 scores of 10 or higher) and a self-reported diagnosis of hypertension
Intervention heart health
Duration 8-week program; surveys at baseline, 4 weeks, and 8 weeks post-baseline
Measures Patient Health Questionnaire-9 (PHQ-9), systolic blood pressure
Topics Depression Meditation
Key points The trial is designed to estimate effect sizes for changes in depressive symptoms (PHQ-9) and systolic blood pressure from baseline to 8 weeks and to assess implementation acceptability, appropriateness, and feasibility. The authors propose that successful completion would provide preliminary evidence for the effectiveness of an adapted mindfulness program and for community-based delivery, but no outcome results are reported in this abstract.

Abstract

Background: Community-based mental health interventions hold potential to reach communities who are less likely to engage in traditional clinic-based services. Partnering with community members and organizations to develop a community-informed approach increases the likelihood of successful implementation of these interventions. We will evaluate the effectiveness and implementation of an adapted mindfulness-based stress reduction intervention among Black/African American adults with comorbid depression and hypertension.

Methods: This trial is a single-arm, type 1 hybrid effectiveness-implementation study. We will recruit Black/African American adults (≥18 years) with elevated depressive symptoms (PHQ-9 scores ≥10) and a self-reported diagnosis of hypertension. All participants will be enrolled in an 8-week mindfulness-based stress reduction program that has been adapted for Black/African American adults, heart health, and community-based delivery. Study participants will complete surveys at baseline and at 4 weeks and 8 weeks post-baseline; blood pressure readings before and after the first and final mindfulness session; and a post-intervention focus group. We will also recruit community members to a community advisory board to advise on trial execution, challenges, implementation, and evaluation. Primary effectiveness outcomes include effect sizes of changes in depressive symptoms (Patient Health Questionnaire-9 scores) and systolic blood pressure from baseline to 8 weeks. The primary implementation outcome of implementation acceptability, appropriateness, feasibility will be assessed using mixed qualitative-quantitative methods.

Discussion: Successful completion of this trial will provide preliminary evidence for the effectiveness of mindfulness for improving depression and blood pressure control as well as the implementation of community-based mindfulness programs. Trial registration ClinicalTrials.gov (NCTXXXXXXXXX)

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Explore topics